CRISPR-based cancer therapies likely to be a disruptive technology in healthcare: GlobalData Read more
Low patient accrual rates cause termination of over 25 per cent rare disease trials: GlobalData Read more
Launch of generic brands for expensive oncology drugs improves treatment affordability and access in India- GlobalData Read more